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Case report 
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Abstract 
A 47-year-old woman who had been treated for systemic lupus erythematosus 
(SLE) with myasthenia gravis (MG), was admitted to our hospital with acute 
onset of severe anemia after administration of isoniazid. Pure red cell aplasia 
(PRCA) was confirmed by elevated serum iron levels, reticulocytopenia and 
bone marrow aspiration showing a remarkable reduction of erythroblasts. Finally, 
cyclosporine A successfully improved PRCA. Although both SLE and MG have 
the potential complication of PRCA, we report here a case of isoniazid-triggered 
PRCA.  
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Introduction 
Pure red cell aplasia (PRCA) is an uncommon hematological disorder (1). Severe 
anemia in PRCA is associated with a marked reduction of reticulocytes and an 
absence of erythroblast in bone marrow (1). Although primary PRCA is a chronic 
hematological disorder, secondary PRCA can be caused by viral infections, 
autoimmune disorders or drugs (2). Autoimmune disorders such as systemic 
lupus erythematosus (SLE) and myasthenia gravis (MG) complicated with 
thymoma are occasionally reported to be predisposed to PRCA (3). A possible 
cause is drug-induced PRCA which is reported in up to 5% of cases. Here, we 
report a rare case of isoniazid-triggered PRCA in a patient with SLE and MG.  
 
Case report 
A 47-year-old woman had been diagnosed with SLE and was treated with 20 mg 
of oral prednisolone in 1995. Although she was taking 2 mg of oral prednisolone 
daily, she developed ocular type MG with right blepharoptosis that showed a 
positive tensilon test and positive acetylcholine receptor binding antibodies, 
without thymoma. Because she experienced diplopia, she began taking 180 mg of 
pyridostigmine bromide, 10 mg of oral prednisolone and 200 mg of mizoribine in 
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2001. As of 2006, she was taking 3 mg of tacrolimus and 11 mg of oral 
prednisolone daily. Because her mother died of pulmonary tuberculosis, she 
began taking prophylactic isoniazid on September 26th, 2008. On October 4th, she 
became extremely fatigued and had heart palpitations while walking the dog. 
Upon admission to the hospital, she became fatigued with a low grade fever and 
breathlessness with exertion.  
Her hemoglobin level was significantly reduced from 10.8 g/dl on 
September 3rd to 5.8 g/dl on October 24th (Fig. 1) with remarkable reduction of 
reticulocytes (1,000/μl; normal: 25,000-75,000/μl), normal leukocyte and platelet 
counts. An increase in serum iron (225 μg/dl; normal: 48-154 μg/dl) with a 
decrease in unsaturated iron binding (13 μg/dl; normal: 108-325 μg/dl) was 
found along with normal haptoglobin levels (70.3 mg/dl). Serum folic acid and 
vitamin B12 levels were within normal limits. IgM and IgG antibodies specific 
for parvovirus B19 and hepatitis B antigen were negative. Furthermore, both 
parvovirus B19 and Epstein-Barr virus deoxyribonucleic acid was not detected 
by polymerase chain reaction. Serum IgG and anti-double-stranded 
deoxyribonucleic acid antibodies were elevated to 2030 mg/dl (normal: 870-1700 
mg/dl) and 88.4 U/ml (normal<12 U/ml) with reduced complement 3 (59.8 
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mg/dl; normal: 65-135 mg/dl) and normal C-reactive protein (0.04 mg/dl; 
normal<0.17 mg/dl). Chest computed tomography in September 2008 showed 
neither thymoma nor swelling of the lymph nodes.  
Because acute progression of anemia was observed immediately after 
taking isoniazid, its administration was ceased on October 24th. To conduct the 
hematological differential diagnosis, bone marrow aspiration was performed on 
October 29th, resulting in the diagnosis of PRCA according to Casadevall criteria 
(4) accompanied by a decrease in erythroblast. In addition, no malignant cells 
were observed with normal myeloid cells and megakaryocytes. Although nine 
cycles of red blood cell transfusion were performed, administration of daily 
cyclosporine A (CyA) was required due to the protracted recovery of PRCA. 
When a trough level of 157.3 ng/ml was reached using 300 mg of CyA, the 
hemoglobin and reticulocyte counts were gradually improved without blood 
transfusion (Fig. 1). On February 20th, 2009, reticulocyte counts reached 147,000 
with a concomitant improvement of serum iron levels to 130 μg/dl and 
hemoglobin levels to 8.3 g/dl. 
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Discussion 
 Liver dysfunction and peripheral neuropathy are known to be common 
adverse side effects of isoniazid, however, isoniazid-induced PRCA has been 
rarely reported. Some reports (5, 6) showed isoniazid-induced PRCA which was 
rapidly improved by withdrawal of the drug. Erslev et al. (7) previously reviewed 
the pathologic condition of PRCA, in which they listed 26 drugs as causative 
agents including isoniazid for PRCA. Although the detailed mechanism of 
drug-induced PRCA remains unclear, diphenylhydantoin, an anti-epileptic agent, 
was shown to be a possible inducer of PRCA through a specific antibody toward 
the agent (8). Thus, a similar mechanism of antibody-dependent cytotoxicity 
might account for isoniazid-related PRCA. 
 Autoimmune diseases such as SLE or MG can be associated with the 
pathogenesis of PRCA. Mizobuchi et al. (9) reviewed 28 published cases of 
PRCA that were complicated with MG and thymoma. Although MG could be 
complicated with PRCA with or without a thymoma, a T cell-mediated 
immunological response is assumed in both cases. The association between 
PRCA and SLE is relatively rare. Habib et al. (10) reported that most of the cases 
of PRCA were diagnosed after, or concomitantly with, the diagnosis of SLE. 
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However, the characteristics of SLE were reported to be similar despite the 
diagnosis of PRCA. As to the mechanism of PRCA in SLE, a T cell-mediated 
immune response is a possibility in both SLE and MG. In support of this idea, 
Arcasoy et al. (11) conducted hematopoietic progenitor cell assays in which the 
defect of burst-forming unit-erythroid colony formation was restored by T cell 
depletion. 
Preferential utilization of CyA for treatment of PRCA has been 
established due to its effectiveness. A nationwide cohort study of CyA treatment 
for acquired PRCA was done in Japan (12). The results showed a sustained, 
relapse-free survival in CyA-containing regimens compared to treatment with 
corticosteroid alone. CyA has the potential to inhibit T cell activation through 
inhibition of nuclear translocation of the nuclear factor of activated T cells 
(NF-AT). Thus, in our case, T-cell mediated cytotoxicity of the underlying 
autoimmune mechanism might be an appropriate indication. 
 In summary, the present case of PRCA is thought to be triggered by 
isoniazid due to its clinical course. Considering the prolonged recovery period 
after administration of isoniazid, we insist that existence of both MG and SLE 
protracted the course of PRCA based on a T cell-mediated mechanism in our case. 
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Therefore, isoniazid would be merely an inducer of T cell-mediated cytotoxicity. 
Additional studies of drug-related PRCA under the presence of autoimmune 
diseases are required to elucidate the mechanism of action in isoniazid-induced 
PRCA. 
  
Abbreviations; CyA; cyclosporine A, SLE; systemic lupus erythematosus, MG; 
myasthenia gravis, PRCA; pure red cell aplasia 
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Figure legend 
Figure 1 Clinical course of pure red cell aplasia (PRCA) of the patient with 
systemic lupus erythematosus (SLE) combined with myasthenia gravis (MG) 
The patient was pretreated with 11 mg of oral prednisolone and 3mg of 
taclorimus for SLE and MG. Immediately thereafter she took 200 mg of isoniazid 
and severe anemia appeared with remarkable reduction of reticulocytes, which 
was confirmed as PRCA by bone marrow aspiration. Since discontinuation of 
isoniazid and repeated blood transfusions were not effective for recovery of 
anemia, cyclosporine A (CyA) was substituted for taclorimus. After the trough 
level of CyA reached 157.3 ng/ml, the reticulocyte and hemoglobin levels were 
recovered without additional blood transfusions. PSL; prednisolone, MZR; 
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